The use of immune modulating drugs for the treatment of multiple sclerosis
Open Access
- 1 January 2016
- journal article
- review article
- Published by Armed Forces Medical Services in Neurosciences
- Vol. 21 (1) , 4-9
Abstract
This review discusses the mechanisms of action of 4 immune modulating drugs currently used in the treatment of multiple sclerosis (MS), including Alemtuzumab, a humanized monoclonal antibody that functions by targeting CD52, an antigen primarily expressed on T and B lymphocytes and monocytes/macrophages, resulting in their depletion and subsequent repopulation; Dimethyl fumarate that switches cytokine production toward a T helper 2 profile and enhances cytosolic levels of nuclear factor erythroid 2–related factor 2, which has immune regulatory and cytoprotective effects on oligodendrocytes, neurons, and glial cells; Fingolimod functions by blocking the release of activated lymphocytes from lymph nodes by targeting sphingosin-1-phosphate receptors; Natalizumab a humanized monoclonal antibody binds a4b1-integrin resulting in reduced migration of immune cells from blood across the blood-brain barrier into the CNS. This review presents the most up to date information on mechanisms of action, safety, and efficacy of these immune modulators and provides future perspectives for the treatment of MS.Keywords
This publication has 45 references indexed in Scilit:
- Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patientsMultiple Sclerosis Journal, 2015
- Dimethyl fumarate inhibits integrin α 4 expression in multiple sclerosis modelsAnnals of Clinical and Translational Neurology, 2015
- Thyroid papillary carcinoma after alemtuzumab therapy for MSJournal of Neurology, 2014
- Therapies for multiple sclerosis: translational achievements and outstanding needsTrends in Molecular Medicine, 2013
- Reprogramming the immune repertoire with alemtuzumab in MSNature Reviews Neurology, 2013
- Dimethyl fumarate for multiple sclerosisExpert Opinion on Investigational Drugs, 2010
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Plasma cytokines in women with chronic fatigue syndromeJournal of Translational Medicine, 2009
- Multiple sclerosisThe Lancet, 2008
- Understanding multiple sclerosis fatigue: A synthesis of biological and psychological factorsJournal of Psychosomatic Research, 2006